Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVS CVS Health	$90.97 -2.2%	$82.07	$58.50 ▼ $98.43	$116.08B	0.6	8.31 million shs	9.73 million shs
GH Guardant Health	$129.69 -2.6%	$95.08	$38.03 ▼ $133.97	$17.20B	1.48	2.19 million shs	3.51 million shs
RPRX Royalty Pharma	$55.76 +2.3%	$49.89	$32.29 ▼ $56.07	$32.11B	0.4	3.38 million shs	17.99 million shs
TEM Tempus AI	$50.47 -1.6%	$48.73	$41.73 ▼ $104.32	$9.06B	3.99	6.17 million shs	11.77 million shs

7 Stocks to Ride The A.I. Megaboom

We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVS CVS Health	0.00%	-2.44%	+9.02%	+14.08%	+45.78%
GH Guardant Health	0.00%	+9.03%	+48.93%	+38.12%	+239.59%
RPRX Royalty Pharma	0.00%	+2.31%	+11.32%	+20.67%	+70.89%
TEM Tempus AI	0.00%	+9.29%	-9.03%	-5.22%	-5.13%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVS CVS Health	$90.97 -2.2%	$82.07	$58.50 ▼ $98.43	$116.08B	0.6	8.31 million shs	9.73 million shs
GH Guardant Health	$129.69 -2.6%	$95.08	$38.03 ▼ $133.97	$17.20B	1.48	2.19 million shs	3.51 million shs
RPRX Royalty Pharma	$55.76 +2.3%	$49.89	$32.29 ▼ $56.07	$32.11B	0.4	3.38 million shs	17.99 million shs
TEM Tempus AI	$50.47 -1.6%	$48.73	$41.73 ▼ $104.32	$9.06B	3.99	6.17 million shs	11.77 million shs

7 Stocks to Ride The A.I. Megaboom

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVS CVS Health	0.00%	-2.44%	+9.02%	+14.08%	+45.78%
GH Guardant Health	0.00%	+9.03%	+48.93%	+38.12%	+239.59%
RPRX Royalty Pharma	0.00%	+2.31%	+11.32%	+20.67%	+70.89%
TEM Tempus AI	0.00%	+9.29%	-9.03%	-5.22%	-5.13%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVS CVS Health	2.85	Moderate Buy	$98.88	8.70% Upside
GH Guardant Health	2.86	Moderate Buy	$129.79	0.08% Upside
RPRX Royalty Pharma	3.00	Buy	$53.71	-3.67% Downside
TEM Tempus AI	2.50	Moderate Buy	$68.64	36.01% Upside

Current Analyst Ratings Breakdown

Latest CVS, RPRX, TEM, and GH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2026	GH Guardant Health	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy
5/27/2026	GH Guardant Health	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$155.00 ➝ $160.00
5/26/2026	GH Guardant Health	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$145.00 ➝ $155.00
5/26/2026	CVS CVS Health	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$101.00 ➝ $106.00
5/21/2026	GH Guardant Health	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$127.00
5/21/2026	GH Guardant Health	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/20/2026	CVS CVS Health	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$102.00 ➝ $110.00
5/15/2026	RPRX Royalty Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
5/14/2026	CVS CVS Health	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$90.00 ➝ $104.00
5/14/2026	CVS CVS Health	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$93.00 ➝ $106.00
5/12/2026	GH Guardant Health	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$135.00

(Data available from 5/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVS CVS Health	$407.91B	0.28	$14.89 per share	6.11	$60.85 per share	1.49
GH Guardant Health	$982.02M	17.51	N/A	N/A	($1.37) per share	-94.66
RPRX Royalty Pharma	$2.38B	13.50	$4.78 per share	11.67	$17.26 per share	3.23
TEM Tempus AI	$1.36B	6.64	N/A	N/A	$2.32 per share	21.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVS CVS Health	$1.77B	$2.27	40.07	10.89	0.89	0.72%	11.88%	3.54%	7/30/2026 (Estimated)
GH Guardant Health	-$416.28M	-$3.39	N/A	N/A	N/A	-40.10%	N/A	-26.42%	7/29/2026 (Estimated)
RPRX Royalty Pharma	$770.95M	$1.47	37.93	10.12	1.53	33.88%	29.25%	14.71%	8/5/2026 (Estimated)
TEM Tempus AI	-$245.03M	-$1.72	N/A	N/A	N/A	-22.20%	-53.83%	-11.17%	8/14/2026 (Estimated)

Latest CVS, RPRX, TEM, and GH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2026	Q1 2026	CVS CVS Health	$2.21	$2.57	+$0.36	$2.30	$94.99 billion	$100.43 billion
5/6/2026	Q1 2026	RPRX Royalty Pharma	$1.22	$1.30	+$0.08	$0.67	$881.69 million	$630.58 million
5/5/2026	Q1 2026	TEM Tempus AI	-$0.21	-$0.13	+$0.08	-$0.71	$345.44 million	$348.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVS CVS Health	$2.66	2.92%	+5.87%	117.18%	4 Years
GH Guardant Health	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	$0.94	1.69%	+24.01%	63.95%	5 Years
TEM Tempus AI	N/A	N/A	N/A	N/A	N/A

Latest CVS, RPRX, TEM, and GH Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/17/2026	RPRX Royalty Pharma	quarterly	$0.2350	1.78%	5/15/2026	5/15/2026	6/10/2026
3/18/2026	CVS CVS Health	quarterly	$0.6650	3.37%	4/23/2026	4/23/2026	5/4/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVS CVS Health	0.78	0.87	0.66
GH Guardant Health	N/A	4.68	4.39
RPRX Royalty Pharma	0.86	2.66	2.66
TEM Tempus AI	2.96	3.31	3.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVS CVS Health	80.66%
GH Guardant Health	92.60%
RPRX Royalty Pharma	54.35%
TEM Tempus AI	24.22%

Insider Ownership

Company	Insider Ownership
CVS CVS Health	0.85%
GH Guardant Health	5.60%
RPRX Royalty Pharma	18.84%
TEM Tempus AI	24.26%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVS CVS Health	300,000	1.28 billion	1.27 billion	Optionable
GH Guardant Health	2,506	132.60 million	125.17 million	Not Optionable
RPRX Royalty Pharma	80	575.83 million	467.35 million	Optionable
TEM Tempus AI	3,800	179.57 million	136.00 million	N/A

CVS, RPRX, TEM, and GH Headlines

Recent News About These Companies

Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development

May 31 at 8:30 AM | businesswire.com

Tempus AI, Inc. $TEM Shares Bought by Legal & General Group Plc

May 31 at 4:58 AM | marketbeat.com

Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results

May 31 at 4:26 AM | finance.yahoo.com

Tempus Introduces 'Preview': Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results

May 30 at 11:00 AM | gurufocus.com

Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community

May 30 at 8:30 AM | businesswire.com

Tempus Introduces ‘Preview': Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results

May 30 at 8:00 AM | businesswire.com

Tempus AI (NASDAQ:TEM) CEO Eric Lefkofsky Sells 166,250 Shares

May 30 at 7:21 AM | insidertrades.com

Tempus AI, Inc. (TEM) Analyst/Investor Day - Slideshow

May 30 at 5:32 AM | seekingalpha.com

Traders Purchase High Volume of Tempus AI Call Options (NASDAQ:TEM)

May 30 at 4:22 AM | americanbankingnews.com

"AI that predicts clinical outcomes?" Tempus AI in focus after ASCO data reveal

May 30 at 1:30 AM | seekingalpha.com

How The Tempus AI (TEM) Investment Story Is Shifting As Analysts Rework Their Models

May 30 at 1:30 AM | finance.yahoo.com

TD Cowen Remains a Hold on Tempus AI, Inc. Class A (TEM)

May 29 at 3:27 PM | theglobeandmail.com

Investors Buy Large Volume of Tempus AI Call Options (NASDAQ:TEM)

May 29 at 12:16 PM | marketbeat.com

Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology

May 29 at 9:15 AM | businesswire.com

Baker Avenue Asset Management LP Buys New Stake in Tempus AI, Inc. $TEM

May 29 at 3:13 AM | marketbeat.com

Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology

May 28 at 8:30 AM | businesswire.com

HIMS vs. TEM: Which AI Healthcare Stock Offers Better Upside Now?

May 27, 2026 | zacks.com

Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows

May 27, 2026 | businesswire.com

Tempus AI Expands Precision Oncology With New Prostate Test And ASCO Data

May 27, 2026 | finance.yahoo.com

Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 26, 2026 | timesargus.comT

Wellington Shields Capital Management LLC Buys Shares of 23,594 Tempus AI, Inc. $TEM

May 26, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CVS, RPRX, TEM, and GH Company Descriptions

CVS Health NYSE:CVS

$90.96 -2.01 (-2.16%)

Closing price 05/29/2026 03:59 PM Eastern

Extended Trading

$91.22 +0.25 (+0.27%)

As of 05/29/2026 07:54 PM Eastern

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, LTC pharmacies and on-site pharmacies, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.

Guardant Health NASDAQ:GH

$129.69 -3.53 (-2.65%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$129.08 -0.61 (-0.47%)

As of 05/29/2026 07:58 PM Eastern

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Royalty Pharma NASDAQ:RPRX

$55.76 +1.28 (+2.35%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$55.73 -0.03 (-0.05%)

As of 05/29/2026 07:58 PM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Tempus AI NASDAQ:TEM

$50.47 -0.82 (-1.60%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$50.38 -0.09 (-0.18%)

As of 05/29/2026 08:00 PM Eastern

Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVS, RPRX, TEM, and GH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVS, RPRX, TEM, and GH Earnings

Compare Dividends

Latest CVS, RPRX, TEM, and GH Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVS, RPRX, TEM, and GH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CVS, RPRX, TEM, and GH Company Descriptions

CVS Health NYSE:CVS

Guardant Health NASDAQ:GH

Royalty Pharma NASDAQ:RPRX

Tempus AI NASDAQ:TEM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools